Letter from the CEO

October 31, 2016

On behalf of the Adgero team, we would like to thank you for your continued support and joining us in supporting Breast Cancer Awareness Month.

Breast cancer is the most common type of cancer in women and the second leading cause of cancer deaths among women in the United States. While initial or primary breast cancer can be treated with a combination of chemotherapy, hormonal therapy, radiation and surgery, survivors may still develop metastatic breast cancer. One form of this is cutaneous metastatic breast cancer (CMBC). This disease occurs when breast cancer recurs locally on the skin and can develop even decades after the initial breast cancer and its subsequent treatment. While most internal cancers can metastasize to the skin, this occurs most commonly with breast cancer.

A 2003 meta-analysis of approximately 20,000 cancer patients found that 24% of breast cancer patients included in the analysis had developed cutaneous metastases, which was the highest rate of any cancer type. Given that approximately 160,000 women suffer from metastatic breast cancer, we believe the prevalence of CMBC may approach 40,000 in the United States.

Cutaneous metastasis occurs when cells from a cancer in the body spread to the skin, and breast cancer is one of the cancers that most commonly metastasizes in this way. Left unchecked, CMBC is a life threatening, highly morbid form of breast cancer characterized by unrelenting progression of multiple cutaneous tumor masses. This disease normally occurs several years after a mastectomy and usually starts near the surgical site as small nodules (tumors). Adgero is focused on building a pipeline by advancing its proprietary late stage photodynamic therapy (PDT) platform with potential broad utility for the treatment of serious oncology indications. Our lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer who have failed radiation therapy.

As October comes to a close and Breast Cancer Awareness Month efforts begin to subside, let us not forget about the importance of standing together, supporting one another, and continue to push forward in advancing the discovery and development of life changing treatment options. We remain devoted to the continued development of our potentially effective therapy for the treatment of CMBC, REM-001 Therapy, which has been shown to induce tumor death by apoptosis, necrosis, vascular shutdown and by a T-cell mediated immune response. For additional information about Adgero and to receive the Company’s latest news, please visit the Adgero website at www.adgerobiopharm.com and connect with the Company on Twitter, Facebook and LinkedIn. Thank you for your time, and for your dedication and efforts in the battle against breast cancer!

Best Regards,

Frank Pilkiewicz, PhD
President & Chief Executive Officer
Adgero Biopharmaceuticals Holdings, Inc.